W.C. Chen et al.
: Immune responses of nanomedicine 211
[29] Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K,
Breen W, Hartsough K, Machemer L, Radka S, Jadhav V, Vaish N,
Zinnen S, Vargeese C, Bowman K, Shaffer CS, Jeffs LB, Judge A,
MacLachlan I, Polisky B. Potent and persistent in vivo anti-HBV
activity of chemically modified siRNAs. Nat. Biotechnol. 2005,
23, 1002–1007.
[30] Zimmermann TS, Lee ACH, Akinc A, Bramlage B, Bumcrot D,
Fedoruk MN, Harborth J, Heyes JA, Jeffs LB, John M, Judge AD,
Lam K, McClintock K, Nechev LV, Palmer LR, Racie T, Röhl I,
Seiffert S, Shanmugam S, Sood V, Soutschek J, Toudjarska I,
Wheat AJ, Yaworski E, Zedalis W, Koteliansky V, Manoharan M,
Vornlocher HP, MacLachlan I. RNAi-mediated gene silencing in
non-human primates. Nature 2006, 441, 111–114.
[31] Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M,
Jayaprakash KN, Jayaraman M, Rajeev KG, Cantley WL,
Dorkin JR, Butler JS, Qin L, Racie T, Sprague A, Fava E,
Zeigerer A, Hope MJ, Zerial M, Sah DW, Fitzgerald K, Tracy MA,
Manoharan M, Koteliansky V, Fougerolles Ad, Maier MA.
Targeted delivery of RNAi therapeutics with endogenous and
exogenous ligand-based mechanisms. Mol. Ther. 2010, 18,
1357–1364.
[32] Judge AD, Bola G, Lee AC, MacLachlan I. Design of
noninflammatory synthetic siRNA mediating potent gene
silencing in vivo. Mol. Ther. 2006, 13, 494–505.
[33] Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I.
Sequence-dependent stimulation of the mammalian innate
immune response by synthetic siRNA. Nat. Biotechnol. 2005,
23, 457–462.
[34] Robbins M, Judge A, Ambegia E, Choi C, Yaworski E, Palmer L,
McClintock K, MacLachlan I. Misinterpreting the therapeutic
effects of small interfering RNA caused by immune stimulation.
Hum. Gene Ther. 2008, 19, 991–999.
[35] Robbins M, Judge A, Liang L, McClintock K, Yaworski E,
MacLachlan I. 2′-O-Methyl-modified RNAs act as TLR7
antagonists. Mol. Ther. 2007, 15, 1663–1669.
[36] Huang L, Liu Y. In vivo delivery of RNAi with lipid-based
nanoparticles. Annu. Rev. Biomed. Eng. 2011, 13, 507–530.
[37] Dams ET, Laverman P, Oyen WJ, Storm G, Scherphof GL, van
Der Meer JW, Corstens FH, Boerman OC. Accelerated blood
clearance and altered biodistribution of repeated injections of
sterically stabilized liposomes. J. Pharmacol. Exp. Ther. 2000,
292, 1071–1079.
[38] Ishida T, Maeda R, Ichihara M, Mukai Y, Motoki Y, Manabe Y,
Irimura K, Kiwada H. The accelerated clearance on
repeated injection of pegylated liposomes in rats:
laboratory and histopathological study. Cell. Mol.
Biol. Lett. 2002, 7, 286.
[39] Laverman P, Carstens MG, Boerman OC, Dams ET, Oyen WJ,
van Rooijen N, Corstens FH, Storm G. Factors affecting the
accelerated blood clearance of polyethylene glycol-liposomes
upon repeated injection. J. Pharmacol. Exp. Ther. 2001, 298,
607–612.
[40] Ishida T, Kiwada H. Accelerated blood clearance (ABC)
phenomenon upon repeated injection of PEGylated liposomes.
Int. J. Pharm. 2008, 354, 56–62.
[41] Shimizu T, Ishida T, Kiwada H. Transport of PEGylated
liposomes from the splenic marginal zone to the follicle
in the induction phase of the accelerated blood clearance
phenomenon. Immunobiology 2012, http://dx.doi.
org/10.1016/j.imbio.2012.08.274.
[42] Ishida T, Harada M, Wang XY, Ichihara M, Irimura K, Kiwada H.
Accelerated blood clearance of PEGylated liposomes following
preceding liposome injection: effects of lipid dose and PEG
surface-density and chain length of the first-dose liposomes.
J. Control. Release 2005, 105, 305–317.
[43] Koide H, Asai T, Hatanaka K, Urakami T, Ishii T, Kenjo E,
Nishihara M, Yokoyama M, Ishida T, Kiwada H, Oku N. Particle
size-dependent triggering of accelerated blood clearance
phenomenon. Int. J. Pharm. 2008, 362, 197–200.
[44] Ishida T, Ichihara M, Wang X, Yamamoto K, Kimura J, Majima E,
Kiwada H. Injection of PEGylated liposomes in rats elicits
PEG-specific IgM, which is responsible for rapid elimination
of a second dose of PEGylated liposomes. J. Control. Release
2006, 112, 15–25.
[45] Suzuki T, Ichihara M, Hyodo K, Yamamoto E, Ishida T,
Kiwada H, Ishihara H, Kikuchi H. Accelerated blood clearance
of PEGylated liposomes containing doxorubicin upon repeated
administration to dogs. Int. J. Pharm. 2012, 436, 636–643.
[46] La-Beck NM, Zamboni BA, Gabizon A, Schmeeda H,
Amantea M, Gehrig PA, Zamboni WC. Factors affecting the
pharmacokinetics of PEGylated liposomal doxorubicin in
patients. Cancer Chemother. Pharmacol. 2012, 69, 43–50.
[47] Tagami T, Nakamura K, Shimizu T, Yamazaki N, Ishida T,
Kiwada H. CpG motifs in pDNA-sequences increase anti-PEG
IgM production induced by PEG-coated pDNA-lipoplexes.
J. Control. Release 2010, 142, 160–166.
[48] Tagami T, Uehara Y, Moriyoshi N, Ishida T, Kiwada H. Anti-PEG
IgM production by siRNA encapsulated in a PEGylated lipid
nanocarrier is dependent on the sequence of the siRNA.
J. Control. Release 2011, 151, 149–154.
[49] Judge A, McClintock K, Phelps JR, Maclachlan I. Hypersensitivity
and loss of disease site targeting caused by antibody responses
to PEGylated liposomes. Mol. Ther. 2006, 13, 328–337.
[50] Cheng WW, Allen TM. The use of single chain Fv as targeting
agents for immunoliposomes: an update on immunoliposomal
drugs for cancer treatment. Expert Opin. Drug Deliv. 2010, 7,
461–478.
[51] Harding JA, Engbers CM, Newman MS, Goldstein NI,
Zalipsky S. Immunogenicity and pharmacokinetic attributes
of poly(ethylene glycol)-grafted immunoliposomes. Biochim.
Biophys. Acta 1997, 1327, 181–192.
[52] Banerji B, Alving CR. Anti-liposome antibodies induced by
lipid A. I. Influence of ceramide, glycosphingolipids, and
phosphocholine on complement damage. J. Immunol. 1981,
126, 1080–1084.
[53] Banerji B, Lyon JA, Alving CR. Membrane lipid composition
modulates the binding specificity of a monoclonal antibody
against liposomes. Biochim. Biophys. Acta 1982, 689,
319–326.
[54] Schuster BG, Neidig M, Alving BM, Alving CR. Production of
antibodies against phosphocholine, phosphatidylcholine,
sphingomyelin, and lipid A by injection of liposomes
containing lipid A. J. Immunol. 1979, 122, 900–905.
[55] Wassef NM, Roerdink F, Swartz GM Jr, Lyon JA, Berson BJ,
Alving CR. Phosphate-binding specificities of monoclonal
antibodies against phosphoinositides in liposomes. Mol.
Immunol. 1984, 21, 863–868.
[56] Wassef NM, Swartz GM Jr, Alving CR, Kates M. Antibodies to
liposomal phosphatidylcholine and phosphatidylsulfocholine.
Biochem. Cell Biol. 1990, 68, 54–58.
212 W.C. Chen et al.: Immune responses of nanomedicine
[57] Gluck R, Walti E. Are anti-phospholipid antibodies to be
expected after proteoliposomal hepatitis A vaccination?
J. Liposome Res. 1996, 6, 415–439.
[58] Rauch J, Janoff AS. Phospholipid in the hexagonal II phase is
immunogenic: evidence for immunorecognition of nonbilayer
lipid phases in vivo. Proc. Natl. Acad. Sci. USA. 1990, 87,
4112–4114.
[59] Di Gioacchino M, Petrarca C, Lazzarin F, Di Giampaolo L,
Sabbioni E, Boscolo P, Mariani-Costantini R, Bernardini G.
Immunotoxicity of nanoparticles. Int. J. Immunopathol.
Pharmacol. 2011, 24 (Suppl. 1), 65S–71S.
[60] Landesman-Milo D, Peer D. Altering the immune response
with lipid-based nanoparticles. J. Control. Release 2012, 161,
600–608.
[61] Lonez C, Vandenbranden M, Ruysschaert JM. Cationic
liposomal lipids: from gene carriers to cell signaling. Prog.
Lipid Res. 2008, 47, 340–347.
Weihsu Claire Chen received a BS in Life Science from the National
Taiwan University and a MS in Immunology from the National
Yang-Ming University, Taiwan. She was a Project Manager in United
Biomedical, Inc. in New York before she went to the University of
Pittsburgh to pursue her PhD in Pharmaceutical Sciences in Profes-
sor Leaf Huang’s laboratory. Her thesis focused on the develop-
ment of liposomal peptide vaccines for treatment of cancers. After
graduating in 2007, Dr. Chen was recruited as a postdoctoral fellow
by Professor James C. Paulson at The Scripps Research Institute
where she developed carbohydrate-modified liposomal nanoparti-
cles to selectively deliver chemotherapeutic drugs to human B cell
lymphoma. She joined the Medicinal Chemistry Platform at Ontario
Institute for Cancer Research in 2010. Dr. Chen is currently a
Scientific Associate in Dr. John E. Dick’s laboratory at Ontario
Cancer Institute where she conducts studies using small molecule
drugs that target leukemia stem cells.
[62] Moyano DF, Goldsmith M, Solfiell DJ, Landesman-Milo D,
Miranda OR, Peer D, Rotello VM. Nanoparticle hydrophobicity
dictates immune response. J. Am. Chem. Soc. 2012, 134,
3965–3967.
[63] Peer D. Immunotoxicity derived from manipulating leukocytes
with lipid-based nanoparticles. Adv. Drug Deliv. Rev. 2012, 64,
1738–1748.
[64] Christensen D, Korsholm KS, Andersen P, Agger EM. Cationic
liposomes as vaccine adjuvants. Expert Rev. Vaccines 2011, 10,
513–521.
[65] Christensen D, Korsholm KS, Rosenkrands I, Lindenstrom T,
Andersen P, Agger EM. Cationic liposomes as vaccine
adjuvants. Expert Rev. Vaccines 2007, 6, 785–796.
[66] Chono S, Li SD, Conwell CC, Huang L. An efficient and low
immunostimulatory nanoparticle formulation for systemic
siRNA delivery to the tumor. J. Control. Release 2008, 131,
64–69.
Jonathan P. May received his MSc in Chemistry from the University
of Durham, UK and his PhD from the University of Southampton,
UK, on the subject of Nucleic Acid Chemistry. His thesis, titled “The
Development of Oligonucleotide Probes for Genetic Analysis,”
focused on the synthesis of novel fluorescent quenchers and duplex
stabilizing moieties for fluorescent probe technologies. His work led
to a marketed product for his PhD CASE award sponsor, Eurogentec,
Belgium. He was then awarded a postdoctoral fellowship from The
Royal Society, UK, to work on two projects related to DNAzymes and
bicyclic peptide toxins with Prof. David Perrin at University of British
Columbia in Vancouver, Canada. Following this, he took a job at
Vancouver’s CDRD (Center for Drug Research and Development) in
the Medicinal Chemistry division, before moving across the country
to take his current position at the OICR (Ontario Institute for
Cancer Research) working on nanomedicine approaches for
cancer therapy. His current focus is on developing HaT technology,
a thermosensitive liposomal formulation for the delivery of
chemotherapeutic drugs to tumors with reduced systemic exposure.
 W.C. Chen et al.: Immune responses of nanomedicine 213

Shyh-Dar Li received a BS in Pharmacy and a MS in Pharmaceuti-

cal Sciences from the National Taiwan University. He then joined
the Industrial Technology Research Institute in Taiwan, where he
invented two nanomedicine technologies for delivering oligonu-
cleotides and peptides to tumors and the brain. These technologies
have been licensed by Andros Pharmaceuticals (Taiwan) and to BBB
Technologies (The Netherlands). Dr. Li obtained his PhD in Pharma-
ceutical Sciences from the University of North Carolina at Chapel
Hill under Dr. Leaf Huang’s supervision. His thesis project focused
on developing tumor-targeted nanoparticles for siRNA delivery, and
this technology along with others from the Huang laboratory led
to the launch of a start-up company, Qualiber. Dr. Li completed his
postdoctoral training with Dr. Stephen Howell at the University of
California, San Diego, where he developed a polysaccharide con-
jugate of cisplatin for intraperitoneal chemotherapy. He joined the
Ontario Institute for Cancer Research as a Principal Investigator in
2009 focusing on drug delivery research. His laboratory has created
two proprietary technologies to enhance cancer chemotherapy,
including a thermosensitive liposomal formulation (HaT) and a poly-
meric conjugate platform (Cellax). His work has been published in
scholarly journals and his laboratory has been supported by major
funding agencies in Canada and the US.